Evidence map›Paper›PMID 19758996›Full record

ArticleThe Journal of biological chemistry2009

Caspase-9 activation by the apoptosome is not required for fas-mediated apoptosis in type II Jurkat cells.

Mary E Shawgo, Shary N Shelton, John D Robertson

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mary E ShawgoDepartment of Pharmacology, Toxicology & Therapeutics and the Kansas University Cancer Center, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
Shary N Shelton
John D Robertson
The University of Kansas Cancer Center · US

Funding

UNDERSTANDING THE ROLE OF SMALL RNAS IN ARABIDOPSIS POLLEN DEVELOPMENTP20RR016475 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ACKLEY, BRIAN DOUGLAS · 2001 to 2011
$38.1M
XRAY CRYSTALLOGRAPHY CORE (JANUARY 1 - JUNE 30, 2005)P20RR016443 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SLUSSER, JOYCE GENEINE · 2001 to 2010
$21.3M
TRAINING PROGRAM IN ENVIRONMENTAL TOXICOLOGYT32ES007079 · NIEHS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI HAGENBUCH, BRUNO · 1985 to 2015
$4.1M
Topoisomerase II-directed drugs and cell deathK22ES011647 · NIEHS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROBERTSON, JOHN D · 2004 to 2006
$319k
NCRR NIH HHS P20 RR016443NCRR NIH HHS P20 RR016475NIEHS NIH HHS K22 ES011647NIEHS NIH HHS T32 ES007079
6 · The paper itself

Abstract

Activation of executioner caspases during receptor-mediated apoptosis in type II cells requires the engagement of the mitochondrial apoptotic pathway. Although it is well established that recruitment of mitochondria in this context involves the cleavage of Bid to truncated Bid (tBid), the precise post-mitochondrial signaling responsible for executioner caspase activation is controversial. Here, we used distinct clones of type II Jurkat T-lymphocytes in which the mitochondrial apoptotic pathway had been inhibited to investigate the molecular requirements necessary for Fas-induced apoptosis. Cells overexpressing either Bcl-2 or Bcl-x(L) were protected from apoptosis induced by agonistic anti-Fas antibody. By comparison, Apaf-1-deficient Jurkat cells were sensitive to anti-Fas, exhibiting Bid cleavage, Bak activation, the release of cytochrome c and Smac, and activation of executioner caspase-3. Inhibiting downstream caspase activation with the pharmacological inhibitor Z-DEVD-fmk or by expressing the BIR1/BIR2 domains of X-linked inhibitor of apoptosis protein (XIAP) decreased all anti-Fas-induced apoptotic changes. Additionally, pretreatment of Bcl-x(L)-overexpressing cells with a Smac mimetic sensitized these cells to Fas-induced apoptosis. Combined, our findings strongly suggest that Fas-mediated activation of executioner caspases and induction of apoptosis do not depend on apoptosome-mediated caspase-9 activation in prototypical type II cells.

Indexed as

ApoptosisApoptosomesApoptotic Protease-Activating Factor 1bcl-X ProteinBlotting, WesternCaspase 3Caspase 7Caspase 9Cytochromes c'Enzyme Activationfas ReceptorFlow CytometryGene Knockdown TechniquesHumansJurkat CellsMembrane Potential, MitochondrialAPAF1 protein, humanApoptosomesApoptotic Protease-Activating Factor 1BCL2L1 protein, humanbcl-X ProteinCaspase 3Caspase 7Caspase 9Cytochromes c'fas ReceptorProto-Oncogene Proteins c-bcl-2XIAP protein, humanX-Linked Inhibitor of Apoptosis Protein

Identifiers

PMID19758996
PMCPMC2785189
OpenAlexW2053243170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.